These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 18591268)
41. Effects of continuous or pulsed exposure to rifabutin and sparfloxacin on the intracellular growth of Staphylococcus aureus and Mycobacterium tuberculosis. Fietta A; Morosini M; Cascina A J Chemother; 2001 Apr; 13(2):167-75. PubMed ID: 11330364 [TBL] [Abstract][Full Text] [Related]
42. Rifabutin encapsulated in liposomes exhibits increased therapeutic activity in a model of disseminated tuberculosis. Gaspar MM; Cruz A; Penha AF; Reymão J; Sousa AC; Eleutério CV; Domingues SA; Fraga AG; Filho AL; Cruz ME; Pedrosa J Int J Antimicrob Agents; 2008 Jan; 31(1):37-45. PubMed ID: 18006283 [TBL] [Abstract][Full Text] [Related]
43. Sustained release of isoniazid from a single injectable dose of poly (DL-lactide-co-glycolide) microparticles as a therapeutic approach towards tuberculosis. Dutt M; Khuller GK Int J Antimicrob Agents; 2001 Feb; 17(2):115-22. PubMed ID: 11165115 [TBL] [Abstract][Full Text] [Related]
44. Mouse model for efficacy testing of antituberculosis agents via intrapulmonary delivery. Gonzalez-Juarrero M; Woolhiser LK; Brooks E; DeGroote MA; Lenaerts AJ Antimicrob Agents Chemother; 2012 Jul; 56(7):3957-9. PubMed ID: 22547626 [TBL] [Abstract][Full Text] [Related]
45. Spray-dried particles as pulmonary delivery system of anti-tubercular drugs: design, optimization, in vitro and in vivo evaluation. Garg T; Goyal AK; Rath G; Murthy RS Pharm Dev Technol; 2016 Dec; 21(8):951-960. PubMed ID: 26334961 [TBL] [Abstract][Full Text] [Related]
46. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Ahmad Z; Sharma S; Khuller GK Int J Antimicrob Agents; 2005 Oct; 26(4):298-303. PubMed ID: 16154726 [TBL] [Abstract][Full Text] [Related]
48. Pharmacokinetics of isoniazid in pulmonary tuberculosis--a comparative study at two dose levels. Roy V; Tekur U; Chopra K Indian Pediatr; 1996 Apr; 33(4):287-91. PubMed ID: 8772902 [TBL] [Abstract][Full Text] [Related]
49. Isoniazid-gelatin conjugate microparticles containing rifampicin for the treatment of tuberculosis. Manca ML; Cassano R; Valenti D; Trombino S; Ferrarelli T; Picci N; Fadda AM; Manconi M J Pharm Pharmacol; 2013 Sep; 65(9):1302-11. PubMed ID: 23927468 [TBL] [Abstract][Full Text] [Related]
50. Preclinical Development of Inhalable d-Cycloserine and Ethionamide To Overcome Pharmacokinetic Interaction and Enhance Efficacy against Ranjan R; Srivastava A; Bharti R; Roy T; Verma S; Ray L; Misra A Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30962335 [TBL] [Abstract][Full Text] [Related]
51. Pulmonary Delivery of Anti-Tubercular Drugs Using Ligand Anchored pH Sensitive Liposomes for the Treatment of Pulmonary Tuberculosis. Bhardwaj A; Grobler A; Rath G; Goyal AK; Jain AK; Mehta A Curr Drug Deliv; 2016; 13(6):909-22. PubMed ID: 26718489 [TBL] [Abstract][Full Text] [Related]
52. Chemotherapeutic activity against murine tuberculosis of once weekly administered drugs (isoniazid and rifampicin) encapsulated in liposomes. Labana S; Pandey R; Sharma S; Khuller GK Int J Antimicrob Agents; 2002 Oct; 20(4):301-4. PubMed ID: 12385689 [TBL] [Abstract][Full Text] [Related]
53. Preparation and characterization of spray dried inhalable powders containing chitosan nanoparticles for pulmonary delivery of isoniazid. Pourshahab PS; Gilani K; Moazeni E; Eslahi H; Fazeli MR; Jamalifar H J Microencapsul; 2011; 28(7):605-13. PubMed ID: 21793647 [TBL] [Abstract][Full Text] [Related]
54. Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects. Ford SL; Chen YC; Lou Y; Borland J; Min SS; Yuen GJ; Shelton MJ Antimicrob Agents Chemother; 2008 Feb; 52(2):534-8. PubMed ID: 18056271 [TBL] [Abstract][Full Text] [Related]
55. Low-dose inhaled versus standard dose oral form of anti-tubercular drugs: concentrations in bronchial epithelial lining fluid, alveolar macrophage and serum. Katiyar SK; Bihari S; Prakash S J Postgrad Med; 2008; 54(3):245-6. PubMed ID: 18626188 [No Abstract] [Full Text] [Related]
56. Pharmacokinetic study of isoniazid and pyrazinamide in children: impact of age and nutritional status. Dayal R; Singh Y; Agarwal D; Kumar M; Swaminathan S; Ramachandran G; Kumar S; Narayan S; Goyal A; Kumar AKH Arch Dis Child; 2018 Dec; 103(12):1150-1154. PubMed ID: 29514812 [TBL] [Abstract][Full Text] [Related]
57. Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice. Deol P; Khuller GK; Joshi K Antimicrob Agents Chemother; 1997 Jun; 41(6):1211-4. PubMed ID: 9174172 [TBL] [Abstract][Full Text] [Related]
58. Inhalable Spray-Dried Chondroitin Sulphate Microparticles: Effect of Different Solvents on Particle Properties and Drug Activity. Rodrigues S; da Costa AMR; Flórez-Fernández N; Torres MD; Faleiro ML; Buttini F; Grenha A Polymers (Basel); 2020 Feb; 12(2):. PubMed ID: 32059360 [TBL] [Abstract][Full Text] [Related]
59. Engineering of konjac glucomannan into respirable microparticles for delivery of antitubercular drugs. Guerreiro F; Swedrowska M; Patel R; Flórez-Fernández N; Torres MD; Rosa da Costa AM; Forbes B; Grenha A Int J Pharm; 2021 Jul; 604():120731. PubMed ID: 34029661 [TBL] [Abstract][Full Text] [Related]